Schedule 13G ownership disclosure

Spero Therapeutics Inc

Security class unavailable · CUSIP: 84833T103

Event date: 2018-12-31

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
1,376,968
Percent of class
7.5700%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-19-006432
Form type
SC 13G/A
Filer
Atlas Venture Fund IX, L.P.
CIK
CIK 1671219
Filed
Feb 08, 2019
Reporting period
Dec 31, 2018
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub